Lymphadenectomy improves outcome in dogs with resected Kiupel high-grade cutaneous mast cell tumours and overtly metastatic regional lymph nodes.

INTRODUCTION Historically, the prognosis for dogs with stage II Kiupel high-grade cutaneous mast cell tumours has been considered poor. OBJECTIVES The aim of this study was to explore the impact of lymphadenectomy on outcome in dogs with Kiupel high-grade cutaneous mast cell tumours and overt regional lymph node metastasis. MATERIAL AND METHODS Data from dogs with completely staged Kiupel high-grade cutaneous mast cell tumours with overt and/or certain regional lymph node metastasis undergoing excision of the primary tumours and adjuvant medical treatment were extracted. Dogs with a cytological diagnosis of regional lymph node metastasis that did not undergo lymphadenectomy were compared with dogs that underwent lymphadenectomy and had a histological diagnosis of overt lymph node metastasis. RESULTS Forty-nine dogs were included, 18 did not undergo lymphadenectomy while 31 underwent lymphadenectomy. Median time to progression was significantly shorter in dogs that did not undergo lymphadenectomy (150 days, 95% confidence interval: 129 to 170) compared to the other dogs (229 days, 95% confidence interval: 191 to 266). Median survival time was also shorter in dogs that did not undergo lymphadenectomy (250 days, 95% confidence interval: 191 to 308) compared to dogs that underwent lymphadenectomy (371 days, 95% confidence interval: 311 to 430). On multivariable analysis, lack of lymphadenectomy was associated with higher risk of overall tumour progression (hazard ratio: 2.05, 95% confidence interval: 1.02 to 4.13), nodal progression (hazard ratio: 3.4, 95% confidence interval: 1.65 to 7.02) and tumour-related death (hazard ratio 3.63, 95% confidence interval: 1.72 to 7.66), whereas tumour size was associated with higher risk of local recurrence (hazard ratio: 3.61, 95% confidence interval: 1.06 to 13). CLINICAL SIGNIFICANCE Regional lymphadenectomy may improve outcome in dogs with biologically aggressive cutaneous mast cell tumours.

[1]  M. Kiupel,et al.  Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low-grade mast cell tumors and early nodal metastasis undergoing surgery. , 2020, Veterinary and comparative oncology.

[2]  K. Drobatz,et al.  Treating the locoregional lymph nodes with radiation and/or surgery significantly improves outcome in dogs with high-grade mast cell tumors. , 2020, Veterinary and comparative oncology.

[3]  J. Liptak.  Histologic Margins and the Residual Tumour Classification Scheme: Is It Time to Use a Validated Scheme in Human Oncology to Standardize Margin Assessment in Veterinary Oncology? , 2019, Veterinary and comparative oncology.

[4]  E. Morello,et al.  Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours. , 2018, Veterinary and comparative oncology.

[5]  L. Marconato,et al.  Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: A prospective study , 2018, Veterinary and comparative oncology.

[6]  M. Milovancev,et al.  Comparison of histologic margin status in low‐grade cutaneous and subcutaneous canine mast cell tumours examined by radial and tangential sections , 2018, Veterinary and comparative oncology.

[7]  G. Cassali,et al.  Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features , 2018, Veterinary pathology.

[8]  J. Warland,et al.  A retrospective review of treatment and response of high-risk mast cell tumours in dogs. , 2016, Veterinary and comparative oncology.

[9]  D. Thamm,et al.  Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2015, Veterinary and comparative oncology.

[10]  C. Rodriguez,et al.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012). , 2015, Veterinary and comparative oncology.

[11]  V. Grieco,et al.  Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). , 2015, Journal of the American Veterinary Medical Association.

[12]  M. Goldschmidt,et al.  Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. , 2015, Veterinary and comparative oncology.

[13]  J. Warland,et al.  The utility of staging in canine mast cell tumours. , 2014, Veterinary and comparative oncology.

[14]  D. Worley,et al.  NEOPLASTIC DISEASE Correlation of Nodal Mast Cells with Clinical Outcome in Dogs with Mast Cell Tumour and a Proposed Classification System for the Evaluation of Node Metastasis , 2022 .

[15]  G. Davis,et al.  The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010). , 2014, Journal of the American Animal Hospital Association.

[16]  D. Chang,et al.  Lymphatic Territories (Lymphosomes) in a Canine: An Animal Model for Investigation of Postoperative Lymphatic Alterations , 2013, PloS one.

[17]  D. Argyle,et al.  European consensus document on mast cell tumours in dogs and cats. , 2012, Veterinary and comparative oncology.

[18]  M. Taketo,et al.  Significance and mechanism of lymph node metastasis in cancer progression. , 2011, Cancer research.

[19]  J D Webster,et al.  Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior , 2011, Veterinary pathology.

[20]  L. Rigatti,et al.  Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). , 2011, Journal of the American Animal Hospital Association.

[21]  F. Shofer,et al.  Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. , 2009, Veterinary and comparative oncology.

[22]  K. Smith,et al.  Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. , 2007, Veterinary and comparative oncology.

[23]  T. Scase,et al.  Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. , 2007, The Journal of small animal practice.

[24]  R. Hynes,et al.  Lymphatic or Hematogenous Dissemination: How Does a Metastatic Tumor Cell Decide? , 2006, Cell cycle.

[25]  E. Macewen,et al.  Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs , 1984, Veterinary pathology.

[26]  W. Halsted.  I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. , 1907, Annals of surgery.